Department of Ophthalmology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.
Graefes Arch Clin Exp Ophthalmol. 2023 Feb;261(2):467-476. doi: 10.1007/s00417-022-05813-4. Epub 2022 Aug 30.
To evaluate the outcome of Descemet Membrane Endothelial Keratoplasty (DMEK) in eyes with pre-existing glaucoma.
In this retrospective, observational case series we included data of 150 consecutive DMEKs in eyes with pre-existing glaucoma of 150 patients after excluding data of the second treated eye of each patient and of re-DMEKs during follow-up. Cumulative incidences of IOP elevation (IOP > 21 mmHg or ≥ 10 mmHg increase in IOP from preoperative value), post-DMEK glaucoma (need of an additional intervention due to worsening of the IOP), graft rejection, and graft failure rate were analyzed using Kaplan-Meier survival analysis. COX regression analysis was used to evaluate independent risk factors.
The 36-month cumulative incidence of IOP elevation was 53.5% [95 CI 43.5-63.5%] and of post-DMEK glaucoma 36.3% [95 CI 26.3-46.3%]. Graft rejection occurred with a 36-month cumulative incidence of 9.2% [CI 95% 2.3-16.1]. None of the analyzed risk factors increased the risk for the development of graft rejection. The 36-month cumulative incidence of graft failure was 16.6% [CI 95% 8.4-24.8]. Independent risk factors for graft failure were the indication for DMEK "status after graft failure" (n = 16) compared to Fuchs' dystrophy (n = 74) (p = 0.045, HR 8.511 [CI 95% 1.054-68.756]) and pre-existing filtrating surgery via glaucoma drainage device (GDD) (n = 10) compared to no surgery/iridectomy (n = 109) (p = 0.014, HR 6.273 [CI 95% 1.456-27.031]).
The risks of postoperative complications (IOP elevation, post-DMEK glaucoma, graft rejection, and graft failure) in patients with pre-existing glaucoma are high. In particular, pre-existing filtrating surgery via GDD implantation-but not trabeculectomy-and DMEK after graft failure increase the risk of graft failure.
评估在合并青光眼的患眼中行去表皮角膜内皮移植术(DMEK)的效果。
本回顾性观察性病例系列研究排除了每位患者第二只眼的治疗数据和随访期间再次行 DMEK 的数据后,纳入了 150 例合并青光眼的 150 例患者的 150 只连续行 DMEK 手术眼的数据。使用 Kaplan-Meier 生存分析评估眼压升高(IOP>21mmHg 或与术前值相比升高≥10mmHg)、DMEK 术后青光眼(因眼压升高需进行额外干预)、移植物排斥和移植物失败的累积发生率。使用 COX 回归分析评估独立的危险因素。
术后 36 个月时,眼压升高的累积发生率为 53.5%[95%CI 43.5-63.5%],DMEK 术后青光眼的累积发生率为 36.3%[95%CI 26.3-46.3%]。移植物排斥的累积发生率为 36 个月时为 9.2%[95%CI 2.3-16.1%]。分析的危险因素均未增加移植物排斥的风险。术后 36 个月时,移植物失败的累积发生率为 16.6%[95%CI 8.4-24.8%]。DMEK 的适应证为“移植物失败后状态”(n=16)而非 Fuchs 营养不良(n=74)(p=0.045,HR 8.511[95%CI 1.054-68.756])和术前已行青光眼引流装置(GDD)滤过性手术(n=10)而非无手术/虹膜切除术(n=109)(p=0.014,HR 6.273[95%CI 95% 1.456-27.031])是移植物失败的独立危险因素。
在合并青光眼的患者中,术后并发症(眼压升高、DMEK 术后青光眼、移植物排斥和移植物失败)的风险较高。特别是,GDD 植入导致的滤过性手术既往史,但不是小梁切除术,以及移植物失败后行 DMEK 会增加移植物失败的风险。